DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

About this update from Diagnostear Technologies, Inc.

[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, today announced the signing of a Letter of Intent (LOI) with Renovate Biologicals Pvt. Ltd. ("Renovate"), a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx™ in India.","length":494,"tagName":"p"},{"type":"text","content":"The LOI is part of DiagnosTear's global commercialization efforts to expand the Company's footprint into one of the world's largest and fastest-growing ophthalmic markets. Under the agreement, Renovate will exclusively lead market-facing activities for TeaRx™ in India until April 30, 2026 (the "LOI Period"), engaging with ophthalmologists, clinics, and key opinion leaders to assess commercial demand and adoption potential.","length":448,"tagName":"p"},{"type":"text","content":"TeaRx™ is a CE-IVD approved, rapid, point-of-care diagnostic test that provides objective assessment of dry eye disease through tear-fluid analysis. Designed for use directly at the point of care, TeaRx™ addresses a major unmet need in ophthalmology by enabling faster, data-driven clinical decisions without reliance on centralized laboratory testing.","length":352,"tagName":"p"},{"type":"text","content":""India is a strategically important market for DiagnosTear, with a large patient population and growing demand for efficient, point-of-care diagnostic solutions," said Dr. Shimon Gross, CEO of DiagnosTear. "This LOI reflects our continued effort toward building a strong international distribution network and accelerating the commercial rollout of TeaRx™ globally."","length":386,"tagName":"p"},{"type":"text","content":"During the LOI Period, the parties will work together to define the optimal commercial framework for the Indian market, including pricing structure, distribution strategy, and long-term collaboration models, with the objective of progressing toward a definitive commercial agreement by June 1, 2026.","length":299,"tagName":"p"},{"type":"text","content":"The announcement follows a series of recent milestones for DiagnosTear, including ongoing international clinica...

More updates from Diagnostear Technologies, Inc.